Mar 15, 2023 / 07:05PM GMT
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst
So thank you so much. Good afternoon, everybody, and welcome to Barclays Global Healthcare Conference in Miami. Do e-mail us or connect with us on Bloomberg if there are any questions you need to address. My name is Peter Lawson. I'm one of the SMID-cap biotech analysts at Barclays, covering predominantly oncology-related companies. Really happy to have up on stage with me from management from Exscientia. We've got Andrew Hopkins, CEO, Co-founder; and Ben Taylor, CFO. So thanks so much today for the time. Good to see you.
Questions and Answers:
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research AnalystAnd then, I guess, AACR is around the quarter essentially. We have more interesting data kind of emerging, great to kind of walk through some of those molecules. I guess the LSD won the differentiation there and kind of how you design that molecule and how you think it could have a better LSD1. That'll be the first question.
Andrew L. Hopkins<